Relative bioavailability of diazoxide, manufactured at two different international locations, in healthy participants under fasting conditions: an open-label, two-stage, adaptive, sequential two-period crossover study

AAPS Open

Table 3 Frequency of adverse events and nontreatment-emergent adverse events by preferred term

	AEs, n
Preferred Term	Test Treatment	Reference Treatment
Bacterial test positive	1	1
Dry throat	1
Hyperglycemia	1
Hypoglycemia	1
Somnolence^a	1
Urine leukocyte esterase positive	1
Vomiting	1
White blood cells urine positive	1
Dizziness		1
Headache		3
Influenza-like illness		1
Nausea		1
Nitrite urine present		1
Oropharyngeal pain		1
Sinus congestion		1
Urine leukocyte esterase positive		1
White blood cells urine positive		1
Total	8	12

^aNTEAE
AEs adverse events, NTEAE nontreatment emergent adverse event
Test, PROGLICEM® 100 mg hard capsules, Batch No.: 3107A (Merck Sharp & Dohme Corp, USA); reference, PROGLYCEM® 100 mg capsules, Lot No.: 120118 (Merck Canada Inc., Canada)